Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

4B to Partner with Insilico to Develop Small Molecule ALS Treatments

publication date: Aug 31, 2021

4B Technologies, a Suzhou biotech, signed a collaboration agreement with Hong Kong's Insilico, an AI discovery company, to develop innovative small molecule therapies for amyotrophic lateral sclerosis and other major neurological diseases. 4B, which concentrates on novel CNS drugs, has already started Phase I trials of its lead asset for ALS and a rare condition. neuromyelitis optica. Using its knowledge of in neurosciences and CNS drug discovery, 4B has built a portfolio of five candidates for targets that include stroke and Alzheimer's in addition to ALS. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital